secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001140361-24-024789
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore Q1 KIMMTRAK sales $70.3M (+36% YoY); brenetafusp ASCO data; cash $832.8M
--------------------------------------------------------------------------------

- KIMMTRAK net sales $70.3M, up 36% YoY; US $50.0M, Europe $19.0M, international $1.4M.
- Net loss $24.4M ($0.49/sh) vs $19.4M ($0.40/sh) in Q1 2023; R&D $57.5M, SG&A $39.3M.
- Cash $832.8M as of Mar 31, 2024, including $390.2M net from Feb 2024 convertible notes; plans to repay $50M loan.
- Brenetafusp Phase 1/2 data in late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (May 31).
- KIMMTRAK launched in 7 additional countries since Jan 2024; now in 17 countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124024789/0001140361-24-024789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036124024789/ef20028669_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-024789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer